
Vodka Seltzers Recalled Over Cans Mislabeled as Energy Drinks
Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content.
High Noon has issued a recall of two production lots of its vodka seltzer cans, saying that some packages contain cans mislabeled as Celsius Astro Vibe energy drinks, warning that consumption would "result in unintentional alcohol ingestion."
The error occurred "when a shared third-party can supplier for multiple beverage brands mistakenly shipped empty Celsius Astro Vibe cans to High Noon's production facility, which were then filled with High Noon vodka seltzer and packed into High Noon Beach Variety 12-packs," Celsius said in a Wednesday news release.
A press representative at E & J Gallo Winery, which owns High Noon, told Newsweek it "is a small batch," but was unable to provide the exact count.
Why It Matters
The mislabeled cans containing alcohol raise health concerns for many consumers, particularly minors and individuals who avoid alcohol for medical or religious reasons. Health officials and retailers often stress that consuming recalled items can lead to serious illness or injury.
High Noon and Celsius are among the top-selling brands in their respective categories, each holding a significant share of the market. The two companies operate independently and have no financial affiliation.
Rows of Celsius energy drinks are pictured.
Rows of Celsius energy drinks are pictured.
mpi34/MediaPunch /IPX/ AP photos
What to Know
Two production lots of High Noon Beach Variety 12-packs have been recalled, after "some of these packs contain cans that are filled with High Noon vodka seltzer alcohol and are mislabeled as CELSIUS® ASTRO VIBE™ Energy Drink, Sparkling Blue Razz Edition with a silver top," according to the company's July 29 announcement.
The two production lots, High Noon UPC 085000040065 and Celsius UPC 8 89392 00134 1, were shipped to distributors in a handful of states: Florida, Michigan, New York, Ohio, Oklahoma, South Carolina, Virginia and Wisconsin. The mislabeled product was shipped from July 21 to July 23.
Consumers are encouraged to not drink the liquid in these lots and dispose of the Celsius Astro Vibe energy drink. If the cans have the following lot codes printed on the bottom of the can, they should not be consumed: L CCB 02JL25 2:55 to L CCB 02JL25 3:11.
The recall was triggered after High Noon "discovered that a shared packaging supplier mistakenly shipped empty CELSIUS cans to High Noon," the company said.
"Celsius immediately launched a joint investigation with GALLO (parent company of High Noon) and the shared third-party can supplier connected to the mislabeled products," Celsius said in a news release.
The statement continued, "While Celsius was not involved in the production, filling, or distribution of these products, we are working closely with High Noon, GALLO, and the U.S. Food and Drug Administration to ensure consumer awareness and safety. We are actively supporting High Noon's voluntary recall efforts to best protect consumers."
What Happens Next
Customers who purchased the specified High Noon Beach Variety pack should contact High Noon at consumerrelations@highnoonvodka.com.
As of Wednesday, no illnesses have been reported due to the recall.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Business Wire
4 hours ago
- Business Wire
ReShape Lifesciences Announces Shareholder Approval of Merger with Vyome Therapeutics
IRVINE, Calif.--(BUSINESS WIRE)--ReShape Lifesciences ® (Nasdaq: RSLS) announced today that its shareholders have approved all of the proposals necessary to complete the previously announced merger with Vyome Therapeutics, which is expected to be effective for the commencement of trading on Friday, August 15, 2025. The shares of common stock of the combined company are expected to commence trading on The Nasdaq Capital Market under the name Vyome Holdings, Inc. and the trading symbol "HIND." 'Vyome's vision is expansive with several promising assets and we are focused on building a healthcare platform spanning the US-India innovation corridor,' said Krishna Gupta, Chairman of Vyome. 'We look forward to trading as a public company under the meaningful ticker symbol 'HIND', which we expect to be on India's Independence Day – August 15. We have a very entrepreneurial and established board and management team, and we have a deep focus on creating value for our new and existing shareholders.' 'We are grateful for the overwhelming support from our shareholders for this merger with Vyome and the sale of our assets to Biorad Medisys. Vyome is well-positioned for success, and we believe this transaction offers a compelling opportunity for our shareholders as Vyome pursues its growth strategy as a Nasdaq-listed public company,' said Paul Hickey, Chief Executive Officer of ReShape. Maxim Group LLC is serving as financial advisor to ReShape in connection with the transactions and Fox Rothschild LLP is acting as its legal counsel. Chardan is serving as financial advisor to Vyome for the merger and Sichenzia Ross Ference Carmel LLP is acting as its legal counsel. About ReShape Lifesciences ® ReShape Lifesciences ® is America's premier weight loss and metabolic health-solutions company, offering an integrated portfolio of proven products and services that manage and treat obesity and metabolic disease. The FDA-approved Lap-Band ® System provides minimally invasive, long-term treatment of obesity and is an alternative to more invasive surgical stapling procedures such as the gastric bypass or sleeve gastrectomy. The investigational Diabetes Bloc-Stim Neuromodulation™ (DBSN™) system utilizes a proprietary vagus nerve block and stimulation technology platform for the treatment of type 2 diabetes and metabolic disorders. The Obalon ® balloon technology is a non-surgical, swallowable, gas-filled intra-gastric balloon that is designed to provide long-lasting weight loss. For more information, please visit About Vyome Vyome Therapeutics is building a healthcare platform spanning the US-India innovation corridor. Vyome's immediate focus is leveraging its clinical-stage assets to transform the lives of patients with immuno-inflammatory conditions. By applying groundbreaking science and its unique positioning across the US-India innovation corridor, Vyome seeks to deliver lasting value to shareholders in a hyper cost-efficient manner while upholding global standards of quality and safety. To learn more, please visit Forward-Looking Statements Certain statements contained in this document are "forward-looking statements." Examples of such statements include, but are not limited to, statements relating to the anticipated timing and completion of the proposed merger and the combined company's listing on the Nasdaq Stock Market after closing of the proposed merger. ReShape and/or the combined company may not actually achieve the plans, carry out the intentions or meet the expectations or projections disclosed in the forward-looking statements and you should not place undue reliance on these forward-looking statements. Such statements are based on management's current expectations and involve risks and uncertainties. Actual results and performance could differ materially from those projected in the forward-looking statements as a result of many factors, including, without limitation, risks and uncertainties associated with the ability to consummate the proposed merger through the process being conducted by the parties. ReShape disclaims any intent or obligation to update these forward-looking statements to reflect events or circumstances that exist after the date on which they were made.


Business Wire
7 hours ago
- Business Wire
C2N Announces Major Global Expansion, Adds Six New International Partners
ST. LOUIS--(BUSINESS WIRE)-- C2N Diagnostics, LLC ('C2N'), a specialty diagnostics company with a vision to bring Clarity Through Innovation®, is reaching additional global healthcare providers eager to use its PrecivityAD2™ blood test to help diagnose Alzheimer's disease. The PrecivityAD2™ blood test allows healthcare providers to determine the presence or absence of amyloid pathology, a known hallmark of Alzheimer's disease, for patients being evaluated for cognitive complaints through a simple, non-invasive blood test. Dr. Joel Braunstein, CEO of C2N Diagnostics, says, 'These new international partnerships are intended to broaden access to C2N's innovative Precivity™ portfolio of blood tests in markets facing growing healthcare pressures given aging populations." Share The company has secured partnerships with six new clinical reference laboratories and distributors, expanding its footprint to over seven additional countries. C2N's new partnerships are with: C2N also maintains partnerships with leading labs around the world, including Grupo Fleury, Healius, Mayo Clinic Laboratories, and Unilabs, along with a research collaboration with Mediford. Dr. Joel Braunstein, CEO of C2N Diagnostics, says, 'These new international partnerships are intended to broaden access to C2N's innovative Precivity™ portfolio of blood tests in markets facing growing healthcare pressures given aging populations, a lack of dementia specialists, and inadequate PET infrastructure. These partnerships are a testament to the science and research that have already assisted healthcare providers in delivering a clear picture of Alzheimer's disease pathology to patients and their families in many countries. The growing burden of Alzheimer's disease requires the healthcare system to explore new ways to offer less costly and more accessible diagnostic testing, and we look forward to helping more patients around the world receive an early and accurate diagnosis.' The PrecivityAD2™ blood test involves a simple blood draw from the patient and is intended for patients aged 55 and older with signs or symptoms of cognitive impairment who are undergoing evaluation for Alzheimer's disease or other causes of cognitive decline. PrecivityAD2™ Blood Test is Rigorously Analytically and Clinically Validated; Has High Accuracy The Journal of the American Medical Association (JAMA) published a large clinical care study examining the ability of the PrecivityAD2 blood test algorithm to improve the diagnostic accuracy of Alzheimer's disease in primary care settings, where most patients with cognitive concerns turn to for initial answers about their memory loss. The study found the PrecivityAD2™ test result delivered a highly statistically significant accuracy of over 90% at a pre-defined, single binary cutoff compared to cerebrospinal fluid (CSF) analysis or amyloid PET analysis. All C2N's Precivity™ tests are currently performed under the ISO 13485:2016 standard and in the company's CAP accredited, CLIA certified laboratory. About C2N Diagnostics, LLC C2N is a specialty diagnostics company with a vision to bring Clarity Through Innovation®. C2N strives to provide exceptional clinical laboratory services and advanced diagnostic solutions in the field of brain health. C2N's high-resolution mass spectrometry-based biomarker services and products are used for: clinical decision-making to improve patient care, including diagnosis and treatment monitoring; maximizing the quality and efficiency of clinical trials that test novel treatments for neurodegeneration; and providing innovative tools to help healthcare researchers better understand novel mechanisms of disease, identify new treatment targets, and conduct important epidemiologic studies to improve global public health. C2N assays have been used in over 150 Alzheimer's disease and other research studies throughout the U.S. and the world. This includes landmark treatment and prevention trials involving disease-modifying therapies (DMTs) that are changing the trajectory of Alzheimer's disease. C2N has ongoing collaborations with multi-national pharmaceutical and biotech companies, leading academic institutions, National Institute on Aging, Alzheimer's Association, and other non-profits and consortiums in addition to research and distribution partnerships with leading labs around the world including Grupo Fleury, Healius, Mediford, Mayo Clinic Laboratories, and Unilabs. Over 50,000 Precivity™-related biomarker measures have been reported through peer-reviewed publications, with many more manuscripts currently under review. The company acknowledges generous support from National Institute on Aging, GHR Foundation, Alzheimer's Drug Discovery Foundation, BrightFocus Foundation, and Alzheimer's Association. For more information visit


Associated Press
10 hours ago
- Associated Press
The Healing Frequency: INDIBA® 448kHz + 20kHz Is Revolutionizing Recovery For Athletes and Everyone Else
SINGAPORE - Media OutReach Newswire - 7 August 2025 - INDIBA® 448 kHz + 20kHz, a patented frequency system that is transforming how athletes and everyday patients recover from injury, manage pain, and restore mobility. Used worldwide in sports and rehabilitation, it supports faster, safer healing—without medication or downtime. INDIBA® Stands Out by Working Deep Beneath the Surface. INDIBA®'s patented Proionic® System delivers radiofrequency energy at 448kHz + 20kHz, creating deep thermal effects and cellular stimulation from inside out. Unlike surface treatments, it penetrates muscles, joints, and stem cells to promote natural repair and regeneration—non-invasively and without downtime. Two major studies show how INDIBA® stands out: 1. Deep Therapeutic Heat for Lasting Healing A study published in the International Journal of Hyperthermia found that INDIBA® raises deep tissue temperature and maintains therapeutic heat for up to 45 minutes, promoting mobility and faster recovery from stiffness and injury. Because heat does more than soothe it: 2. It Stimulates Cellular Regeneration Research shows INDIBA®'s 448kHz + 20kHz frequency activates stem cells to rebuild cartilage, boost collagen, and heal hard-to-repair tissues—offering new potential for managing osteoarthritis, joint damage, and sports injuries. Why the World's Top Athletes Use INDIBA® When milliseconds matter, elite athletes trust INDIBA®. From world champions to leading football clubs, it's their go-to recovery tool. Explore the INDIBA Hall of Fame and see the champions who rely on this technology. But you don't have to be a pro to feel the difference — everyday users, from parents to fitness lovers, turn to INDIBA® for: Clinics Trust It. Patients Feel It. Science Proves It. INDIBA® is integrated into physiotherapy, sports rehabilitation, and wellness practices worldwide due to its: Used to support recovery, mobility, and pain management, INDIBA® contributes to improved patient comfort and quality of life. Healing Powered by Frequency: INDIBA® 448kHz + 20kHz At its core, INDIBA® is about restoring better movement, relieving pain, and accelerating recovery for everybody, at every stage. That's why it's trusted by clinicians, therapists, and elite athletes around the world. Hashtag: #INDIBA The issuer is solely responsible for the content of this announcement.